Cingulate (CING) Competitors

$4.92 +0.13 (+2.71%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$4.86 -0.05 (-1.12%)

As of 06:48 AM Eastern

CING vs. NBP, MIST, NKTX, KROS, and CNTX

Should you buy Cingulate stock or one of its competitors? MarketBeat compares Cingulate with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cingulate include I-Mab (NBP), Milestone Pharmaceuticals (MIST), Nkarta (NKTX), Keros Therapeutics (KROS), and Context Therapeutics (CNTX). These companies are all part of the "pharmaceutical products" industry.

How does Cingulate compare to I-Mab?

Cingulate (NASDAQ:CING) and I-Mab (NASDAQ:NBP) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

I-Mab's return on equity of 0.00% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cingulate	N/A	-509.72%	-172.37%
I-Mab	N/A	N/A	N/A

In the previous week, I-Mab had 1 more articles in the media than Cingulate. MarketBeat recorded 2 mentions for I-Mab and 1 mentions for Cingulate. Cingulate's average media sentiment score of 0.94 beat I-Mab's score of 0.93 indicating that Cingulate is being referred to more favorably in the media.

Company	Overall Sentiment
Cingulate	Positive
I-Mab	Positive

Cingulate has a beta of -0.81, meaning that its stock price is 181% less volatile than the broader market. Comparatively, I-Mab has a beta of 1.56, meaning that its stock price is 56% more volatile than the broader market.

Cingulate has higher earnings, but lower revenue than I-Mab. I-Mab is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cingulate	N/A	N/A	-$22.45M	-$4.32	N/A
I-Mab	$3.89M	61.54	-$46.27M	-$0.36	N/A

41.3% of Cingulate shares are owned by institutional investors. Comparatively, 38.4% of I-Mab shares are owned by institutional investors. 4.3% of Cingulate shares are owned by company insiders. Comparatively, 22.1% of I-Mab shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cingulate presently has a consensus target price of $34.50, suggesting a potential upside of 601.22%. I-Mab has a consensus target price of $9.00, suggesting a potential upside of 334.78%. Given Cingulate's stronger consensus rating and higher possible upside, research analysts clearly believe Cingulate is more favorable than I-Mab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cingulate	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Cingulate and I-Mab tied by winning 7 of the 14 factors compared between the two stocks.

How does Cingulate compare to Milestone Pharmaceuticals?

Cingulate (NASDAQ:CING) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends and analyst recommendations.

Cingulate currently has a consensus price target of $34.50, indicating a potential upside of 601.22%. Milestone Pharmaceuticals has a consensus price target of $7.50, indicating a potential upside of 336.05%. Given Cingulate's higher probable upside, equities analysts clearly believe Cingulate is more favorable than Milestone Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cingulate	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

41.3% of Cingulate shares are owned by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 4.3% of Cingulate shares are owned by insiders. Comparatively, 19.5% of Milestone Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Cingulate has higher earnings, but lower revenue than Milestone Pharmaceuticals. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cingulate	N/A	N/A	-$22.45M	-$4.32	N/A
Milestone Pharmaceuticals	$1.55M	132.76	-$63.06M	-$0.79	N/A

Cingulate's return on equity of -509.72% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cingulate	N/A	-509.72%	-172.37%
Milestone Pharmaceuticals	N/A	-656.73%	-81.19%

In the previous week, Milestone Pharmaceuticals had 10 more articles in the media than Cingulate. MarketBeat recorded 11 mentions for Milestone Pharmaceuticals and 1 mentions for Cingulate. Cingulate's average media sentiment score of 0.94 beat Milestone Pharmaceuticals' score of 0.31 indicating that Cingulate is being referred to more favorably in the media.

Company	Overall Sentiment
Cingulate	Positive
Milestone Pharmaceuticals	Neutral

Cingulate has a beta of -0.81, suggesting that its stock price is 181% less volatile than the broader market. Comparatively, Milestone Pharmaceuticals has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market.

Summary

Milestone Pharmaceuticals beats Cingulate on 10 of the 15 factors compared between the two stocks.

How does Cingulate compare to Nkarta?

Cingulate (NASDAQ:CING) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends and analyst recommendations.

Cingulate currently has a consensus price target of $34.50, indicating a potential upside of 601.22%. Nkarta has a consensus price target of $11.33, indicating a potential upside of 270.37%. Given Cingulate's higher probable upside, equities analysts clearly believe Cingulate is more favorable than Nkarta.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cingulate	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Nkarta	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

41.3% of Cingulate shares are owned by institutional investors. Comparatively, 80.5% of Nkarta shares are owned by institutional investors. 4.3% of Cingulate shares are owned by insiders. Comparatively, 8.4% of Nkarta shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Nkarta is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cingulate	N/A	N/A	-$22.45M	-$4.32	N/A
Nkarta	N/A	N/A	-$104.08M	-$1.40	N/A

Nkarta's return on equity of -29.75% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cingulate	N/A	-509.72%	-172.37%
Nkarta	N/A	-29.75%	-23.43%

In the previous week, Nkarta had 5 more articles in the media than Cingulate. MarketBeat recorded 6 mentions for Nkarta and 1 mentions for Cingulate. Cingulate's average media sentiment score of 0.94 beat Nkarta's score of 0.81 indicating that Cingulate is being referred to more favorably in the media.

Company	Overall Sentiment
Cingulate	Positive
Nkarta	Positive

Cingulate has a beta of -0.81, suggesting that its stock price is 181% less volatile than the broader market. Comparatively, Nkarta has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market.

Summary

Nkarta beats Cingulate on 9 of the 13 factors compared between the two stocks.

How does Cingulate compare to Keros Therapeutics?

Keros Therapeutics (NASDAQ:KROS) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

Keros Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market. Comparatively, Cingulate has a beta of -0.81, indicating that its stock price is 181% less volatile than the broader market.

Keros Therapeutics presently has a consensus price target of $20.40, indicating a potential upside of 70.14%. Cingulate has a consensus price target of $34.50, indicating a potential upside of 601.22%. Given Cingulate's stronger consensus rating and higher possible upside, analysts clearly believe Cingulate is more favorable than Keros Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Cingulate	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Keros Therapeutics has a net margin of 35.65% compared to Cingulate's net margin of 0.00%. Keros Therapeutics' return on equity of 14.25% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Keros Therapeutics	35.65%	14.25%	13.27%
Cingulate	N/A	-509.72%	-172.37%

In the previous week, Keros Therapeutics and Keros Therapeutics both had 1 articles in the media. Keros Therapeutics' average media sentiment score of 1.89 beat Cingulate's score of 0.94 indicating that Keros Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Keros Therapeutics	Very Positive
Cingulate	Positive

71.6% of Keros Therapeutics shares are held by institutional investors. Comparatively, 41.3% of Cingulate shares are held by institutional investors. 20.6% of Keros Therapeutics shares are held by insiders. Comparatively, 4.3% of Cingulate shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Keros Therapeutics has higher revenue and earnings than Cingulate. Cingulate is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Keros Therapeutics	$244.06M	0.97	$87.01M	$1.82	6.59
Cingulate	N/A	N/A	-$22.45M	-$4.32	N/A

Summary

Keros Therapeutics beats Cingulate on 12 of the 14 factors compared between the two stocks.

How does Cingulate compare to Context Therapeutics?

Context Therapeutics (NASDAQ:CNTX) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

Context Therapeutics has a beta of 1.57, indicating that its stock price is 57% more volatile than the broader market. Comparatively, Cingulate has a beta of -0.81, indicating that its stock price is 181% less volatile than the broader market.

Context Therapeutics presently has a consensus price target of $6.60, indicating a potential upside of 179.66%. Cingulate has a consensus price target of $34.50, indicating a potential upside of 601.22%. Given Cingulate's higher possible upside, analysts clearly believe Cingulate is more favorable than Context Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Cingulate	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Context Therapeutics' return on equity of -59.95% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-59.95%	-54.78%
Cingulate	N/A	-509.72%	-172.37%

In the previous week, Context Therapeutics had 16 more articles in the media than Cingulate. MarketBeat recorded 17 mentions for Context Therapeutics and 1 mentions for Cingulate. Context Therapeutics' average media sentiment score of 1.01 beat Cingulate's score of 0.94 indicating that Context Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Context Therapeutics	Positive
Cingulate	Positive

14.0% of Context Therapeutics shares are held by institutional investors. Comparatively, 41.3% of Cingulate shares are held by institutional investors. 4.8% of Context Therapeutics shares are held by insiders. Comparatively, 4.3% of Cingulate shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Context Therapeutics is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.42	N/A
Cingulate	N/A	N/A	-$22.45M	-$4.32	N/A

Summary

Context Therapeutics beats Cingulate on 10 of the 14 factors compared between the two stocks.

Get Cingulate News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CING and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CING vs. The Competition

Export

Metric	Cingulate	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$58.68M	$3.42B	$6.30B	$12.20B
Dividend Yield	N/A	2.30%	2.79%	5.30%
P/E Ratio	-1.14	18.67	21.03	25.58
Price / Sales	N/A	301.14	548.94	78.80
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	15.87	6.75	9.84	6.66
Net Income	-$22.45M	$24.11M	$3.55B	$333.63M
7 Day Performance	-5.93%	-0.53%	-0.52%	-0.12%
1 Month Performance	-8.04%	0.34%	1.21%	3.93%
1 Year Performance	15.76%	78.62%	41.24%	36.07%

Cingulate Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CING Cingulate	2.6173 of 5 stars	$4.92 +2.7%	$34.50 +601.2%	+25.8%	$58.68M	N/A	N/A	20
NBP I-Mab	3.5276 of 5 stars	$2.05 -2.6%	$9.00 +340.1%	N/A	$236.50M	N/A	N/A	380	Positive News
MIST Milestone Pharmaceuticals	2.6637 of 5 stars	$1.94 +1.8%	$7.50 +287.6%	+44.5%	$231.50M	$1.55M	N/A	30	News Coverage Earnings Report
NKTX Nkarta	3.6178 of 5 stars	$3.26 +2.4%	$11.33 +248.2%	+57.7%	$231.34M	N/A	N/A	140	Earnings Report Analyst Forecast
KROS Keros Therapeutics	3.7061 of 5 stars	$11.58 -3.6%	$20.40 +76.2%	-11.0%	$229.17M	$244.06M	6.36	100	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CING) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cingulate (CING) Competitors

CING vs. NBP, MIST, NKTX, KROS, and CNTX

How does Cingulate compare to I-Mab?

Summary

How does Cingulate compare to Milestone Pharmaceuticals?

Summary

How does Cingulate compare to Nkarta?

Summary

How does Cingulate compare to Keros Therapeutics?

Summary

How does Cingulate compare to Context Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CING vs. The Competition

Cingulate Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cingulate (CING) Competitors

CING vs. NBP, MIST, NKTX, KROS, and CNTX

How does Cingulate compare to I-Mab?

Is CING or NBP more profitable?

Does the media refer more to CING or NBP?

Which has more risk and volatility, CING or NBP?

Which has preferable valuation & earnings, CING or NBP?

Do insiders & institutionals hold more shares of CING or NBP?

Do analysts rate CING or NBP?

Summary

How does Cingulate compare to Milestone Pharmaceuticals?

Do analysts prefer CING or MIST?

Do insiders & institutionals believe in CING or MIST?

Which has better valuation and earnings, CING or MIST?

Is CING or MIST more profitable?

Does the media refer more to CING or MIST?

Which has more risk & volatility, CING or MIST?

Summary

How does Cingulate compare to Nkarta?

Do analysts prefer CING or NKTX?

Do insiders & institutionals believe in CING or NKTX?

Which has better valuation and earnings, CING or NKTX?

Is CING or NKTX more profitable?

Does the media refer more to CING or NKTX?

Which has more risk & volatility, CING or NKTX?

Summary

How does Cingulate compare to Keros Therapeutics?

Which has more risk & volatility, KROS or CING?

Do analysts recommend KROS or CING?

Is KROS or CING more profitable?

Does the media prefer KROS or CING?

Do institutionals & insiders have more ownership in KROS or CING?

Which has stronger earnings & valuation, KROS or CING?

Summary

How does Cingulate compare to Context Therapeutics?

Which has more risk & volatility, CNTX or CING?

Do analysts recommend CNTX or CING?

Is CNTX or CING more profitable?

Does the media prefer CNTX or CING?

Do institutionals & insiders have more ownership in CNTX or CING?

Which has stronger earnings & valuation, CNTX or CING?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CING vs. The Competition

Cingulate Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools